Background & Aims: Neonatal intestinal obstruction
(meconium ileus [MI] ) occurs in 15% of patients with cystic fibrosis (CF). Our aim was to determine the relative contribution of genetic and nongenetic modifiers to the development of this major complication of CF. Methods: A total of 65 monozygous twin pairs, 23 dizygous twin/triplet sets, and 349 sets of siblings with CF were analyzed for MI status, significant covariates, and genome-wide linkage. Results: Specific mutations in the CF transmembrane conductance regulator (CFTR), the gene responsible for CF, correlated with MI, indicating a role for CFTR genotype. Monozygous twins showed substantially greater concordance for MI than dizygous twins and siblings (P ϭ 1 ϫ 10 Ϫ5 ), showing that modifier genes independent of CFTR contribute substantially to this trait. Regression analysis revealed that MI was correlated with distal intestinal obstruction syndrome (P ϭ 8 ϫ 10 Ϫ4 ). Unlike MI, concordance analysis indicated that the risk for development of distal intestinal obstruction syndrome in CF patients is caused primarily by nongenetic factors. Regions of suggestive linkage (logarithm of the odds of linkage Ͼ2.0) for modifier genes that cause MI (chromosomes 4q35.1, 8p23.1, and 11q25) or protect from MI (chromosomes 20p11.22 and 21q22.3) were identified by genome-wide analyses. These analyses did not support the existence of a major modifier gene on chromosome 19 in a region previously linked to MI. Conclusions: The CFTR gene along with 2 or more modifier genes are the major determinants of intestinal obstruction in newborn CF patients, whereas intestinal obstruction in older CF patients is caused primarily by nongenetic factors.
C ystic fibrosis (CF [Mendelian Inheritance in Man 219700])
is an autosomal-recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR [Mendelian Inheritance in Man 602421]). Variation in the CFTR genotype has been associated with some aspects of the CF phenotype such as pancreatic status. 1 On the other hand, many other variable features of CF are not correlated, indicating that factors independent of CFTR genotype play a major role in the complications and course of this otherwise single-gene disorder. 2, 3 Two such features are meconium ileus (MI), a form of intestinal obstruction observed in the neonatal period that occurs in 13%-20% of CF patients, [3] [4] [5] [6] and distal intestinal obstruction syndrome (DIOS), a trait with clinical and pathologic similarities to MI that affects older CF patients. 7, 8 Estimates of the prevalence of DIOS in CF patients vary considerably (2.4%-41.3%), probably because of differences in the diagnostic criteria, length of follow-up evaluation, and age range of the patients studied. [7] [8] [9] [10] Several reports indicate that the recurrence rate of MI in siblings is significantly higher than the prevalence of MI in unrelated patients, suggesting that factors shared among siblings contribute to the development of MI. 4, [11] [12] [13] However, it is not known whether familial concordance of MI is the result of shared genetic or environmental factors or a combination of both.
Evidence for genetic factors underlying intestinal obstruction has been derived from studies of the CF mouse model. The majority of homozygous CFTR null mice have a severe and usually fatal intestinal obstruction early in life. 14 By capitalizing on strain-specific differences in survival among CFTR null mice, Rozmahel et al 15 were able to locate a modifier locus to the distal portion of mouse chromosome 7. Several other loci for survival from intestinal obstruction in CF mice have since been identified. 16 Zielenski et al 17 postulated that the locus on chromosome 7 responsible for murine intestinal obstruction may contain a gene that is responsible for MI in CF patients. This theory was tested by genotyping 188 CF sibling pairs and parents using 9 microsatellite markers that spanned 7.65 Mb on chromosome 19q13, a region of conserved synteny with the segment of mouse chromosome 7 that was linked to intestinal obstruction. Several markers from this region showed significant linkage with the MI phenotype consistent with the presence of an MI-modifier gene, which was named CF Modifier 1 (CFM1 [Mendelian Inheritance in Man 603855]) within this region. However, the gene (or genes) within the CFM1 region that modifies MI has not been identified.
The CF Twin and Sibling Study in the United States is currently recruiting patients to assess genetic and nongenetic contribution to disease variation in CF. Monozygous (MZ) and dizygous (DZ) twins can differentiate the relative contribution of genetic factors because twins have a high degree of shared environment, but MZ and DZ twins differ in their degree of gene sharing (100% vs 50%). 18 -21 On the other hand, siblings have the same degree of gene sharing as DZ twins (50%), but a lower degree of shared environment, so that a comparison of DZ twins and siblings can estimate environmental contribution. Although recruitment for the CF Twin and Sibling study is not complete, MI and DIOS are sufficiently frequent to perform an analysis of concordance rates among the patients recruited to date. We also performed an initial genome-wide linkage analysis for MI including a re-evaluation of the CFM1 locus.
Materials and Methods

Family Collection
The CF Twin and Sibling Study is a collaborative effort to collect detailed clinical information and DNA samples from affected siblings and their parents. Informed consent was obtained from all subjects before enrollment in the study. Enrollment was based on conclusive diagnosis of CF. 22 The diagnosis of MI was based on the presence of the following features in the newborn period: lack of passage of stool within 24 hours after birth, evidence of obstruction on abdominal radiograph (ground-glass appearance of intestine, air-fluid levels, and/or intra-abdominal calcifications), evidence of colonic abnormality (microcolon on radiograph), and treatment for obstruction (enema or surgery). Some cases were complicated by bilious vomiting, perforation, and/or atresia of the jejunum or ileum. The diagnosis of DIOS was based on the clinical impression of the reporting CF center. A required feature was intestinal obstruction requiring treatment beyond laxatives (eg, oral polyethylene glycol solution, enema, or surgery); radiologic documentation of DIOS was obtained for some, but not all, patients. Pancreatic status was obtained from patient medical records. Pancreatic-insufficient status was determined by a fecal fat test, a fecal elastase test, the appearance of the stool pattern, the presence of oil in the stool, the patient's growth pattern, and/or the complaint of abdominal pains.
DNA Isolation and Genotyping Methods
Genomic DNA was isolated from whole blood using the phenol/chloroform procedure. 23 The zygosity status of twins was determined by AmpFISTR Profiler (Applied Biosystems, Foster City, CA). CFTR genotype was obtained from the patient's medical record. In cases in which CFTR genotyping had not been performed or was incomplete, DNA samples were typed for 58 CFTR alleles by using the Roche polymerase chain reaction-based Line Probe Assay (Roche Molecular Systems, Alameda, CA). 24 DNA samples with 1 or more unidentified CFTR mutations after typing with the Line Probe Assay were subjected to DNA sequencing of all coding regions of CFTR and flanking introns. 25 For genome-wide linkage studies, patients were genotyped by the Marshfield Genotyping Center for 402 polymorphic short tandem repeat (STR) markers with an average spacing of 10 centimorgans (cM), or 7.5 megabases (Mb). The average rate of genotypes determined for the 1161 individuals was 95% (range, 70%-99.8%); identified Mendelian errors numbered 642 (1.1%). The average heterozygosity in the study population was 75% (range, 57%-89%). Single nucleotide polymorphism (SNP) typing was performed using the Centaurion 100K SNP set from Affymetrix (Santa Clara, CA) 26 ; 90,689 markers met quality criteria for inclusion (minor allele frequency at least 1%; genotype obtained in at least 85% of samples) and yielded an average marker spacing of 23.6 kb. The average rate of genotypes determined for the 86 individuals was 96% (range, 80%-100%); identified Mendelian errors numbered 2115 (0.03%). The average heterozygosity was 30%. For the chromosome 19 -specific map, patients were genotyped at 7 STR markers spanning 6.5 Mb of chr19q13: D19S211, D19S217, D19S219, D19S112, D19S412, D19S902, and D19S604, yielding an average marker spacing of 1.1 Mb. STR markers were sized using an ABI Prism 310 DNA Sequencer or an ABI 3100 DNA Sequencer with GENESCAN analysis software version 3.1.2 (Applied Biosystems, Foster City, CA). Genotyping was controlled internally by genotyping individuals of the same family on the same run. Any ambiguous genotypes and genotypes that were not consistent with Mendelian inheritance were retyped.
Concordance Analysis
Concordance for disease (MI or DIOS) was calculated by the number of pairs concordant for disease divided by the total number of pairs in which at least one member had disease. Concordance for lack of disease was calculated by the number of pairs in which neither member had disease divided by the total number of pairs in which at least one member did not have disease. Heritability estimates were estimated as described by Falconer 27 and Falconer and Mackay. 28 For DIOS concordance calculations, siblings were used as a proxy for DZ twins by correcting the DIOS status for age difference: the DIOS status of the older sibling when he/she was the age of the younger sibling was used. Power calculation was performed using DSTPLAN (M. D. Anderson Cancer Center, Houston, TX). One set of nonidentical triplets in which 1 member had MI and none had DIOS was counted as a single MI discordant pair and as a single pair without DIOS. Three families had a set of MZ twins and a sibling all with CF and contributed to both the MZ and sibling pair concordance calculations. With one exception, the MZ twin set was concordant for disease (MI or DIOS) or lack of disease, and thus was counted as a single individual within a sibling pair. The exception was an MZ twin pair discordant for DIOS with a sibling without DIOS; this set was counted as a single discordant sibling pair.
Statistical Analysis
Statistical calculations were performed using STATA (StataCorp, College Station, TX). For all tests, a P value of less than .05 was considered statistically significant. In case of small cell sizes, the Fisher exact test was used (http://www.unc.edu/ ϳpreacher/fisher/fisher.htm). The Student t test was used to evaluate means derived from normally distributed continuous data. Multiple logistic regression was performed with STATA using clinical data from the CF Twin and Sibling Study. Each clinical variable was tested for correlation with MI along with age and sex in a 3-variable logistic model. Variance was estimated using the robust Huber/White/sandwich estimator, and observations within each family were not considered to be independent. Factors tested individually for correlation with MI were age, sex, DIOS, surgery for DIOS, pancreatic insufficiency, number of ⌬F508 alleles, sweat chloride, positive cultures for Pseudomonas aeruginosa, mucoid pseudomonas, antibiotic-resistant pseudomonas, Burkholderia cepacia, atypical mycobacteria, aspergillus, Staphylococcus aureus, methicillin-resistant S aureus, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, Klebsiella pneumoniae, Escherichia coli, Haemophilus influenzae, streptococcus, sinus disease, surgery for sinus disease, nasal polyps, surgery for nasal polyps, increased transaminase levels, pancreatitis, surgery for pancreatitis, diabetes, cholelithiasis, cholecystectomy, gastroesophageal reflux, Nissen fundoplication, gastrostomy tube placement, rectal prolapse, appendiceal disease, failure to thrive, steatorrhea, neonatal jaundice, average forced expiratory volume in 1 second (CF-specific percentile score 29 ), average body mass index Z-score, age at diagnosis of CF, lung transplantation, number of pulmonary exacerbations in the past 1 or last 5 years, and medication compliance. Factors significantly correlated with MI in the 3-variable analysis were tested for inclusion in a multivariate logistic regression model. Factors were removed if they did not contribute significantly to the risk of MI and their inclusion did not improve the model (likelihood ratio test), or if they were correlated strongly with another covariate. In the final multivariate model, the 3 parameters regarding number of ⌬F508 alleles were correlated (as expected), but no other pair of factors had a correlation coefficient of greater than 0.25.
Genetic Analysis
The genome-wide and chromosome 19 -specific STR marker data were screened for Mendelian inconsistencies by PedCheck 30 and SIB-PAIR 0.99.9 (Queensland University of Medical Research, Queensland, Australia) 31 ; inconsistent markers were retyped or eliminated. Single-and multipoint, parametric and nonparametric linkage analyses were performed using GENE-HUNTER 32 and MERLIN. 33 Parametric analyses were performed with dominant, additive, and recessive models of inheritance with penetrance set at 0.80 and phenocopy rate set at 0.10 (both derived from observed rates of MI; see later), and with alternative penetrance values of 0.60 and 1.00 and phenocopy values of 0.00 and 0.20. Analysis using MERLIN included error detection through identification of improbable recombination events. For analysis of high-density SNP data, MERLIN again was used; for this analysis, linkage disequilibrium between markers was modeled by clustering correlated markers. 34 For the 7-STR map of chromosome 19, SIB-PAIR 0.99.9 31 was used to perform identity-by-descent analyses. If parental genotype data were not available, then identical-bydescent was estimated from identical-by-state. ASP 26.07.2001 35 was used to simulate (n ϭ 1000) the statistical power of our dataset under a dominant (disease allele frequency ϭ 0.10), recessive (disease allele frequency ϭ 0.43), or additive model (disease allele frequency ϭ 0.10), with the disease gene located at a recombination fraction ϭ 0.01 from the simulated marker and a phenocopy rate of 0.05. The earlier-described disease allele frequencies were calculated assuming Hardy-Weinberg equilibrium, a trait prevalence of 15% (derived from the observed rate of MI), and a trait penetrance of 80% (derived from the concordance rate in MZ twins). With disease allele frequency defined as q, calculations were as follows: q 2 ϫ 0.8 ϭ 0.15 giving q ϭ 0.43 for recessive; (1 Ϫ p 2 ) ϫ 0.8 ϭ 0.15 giving p ϭ 0.90 and q ϭ 0.10 for dominant; (2pq ϩ 2q 2 ) ϫ 0.8 ϭ 0.15 giving q ϭ 0.10 for additive. For all 3 models, the number of alleles and the allele frequencies calculated by GENEHUNTER for marker D19S112 were used (13 
Results
Clinical information collected from 65 pairs of MZ twins, 22 pairs of DZ twins, 1 set of nonidentical triplets, 14 single siblings, 365 sibling pairs (includes 4 sibling-MZ twin pairs), 29 sets of 3 siblings, and 1 set of 5 siblings (1009 patients total) was obtained from the CF Twin and Sibling Study. All participants met the diagnostic criteria for CF. These patients account for approximately 85% of all twins affected with CF and 35% of all families with 2 or more children affected with CF in the United States according to the CF Patient Registry maintained by the US CF Foundation. Of the 940 patients with information about MI, 160 had MI (17%); treatment was known in 159 of these: 108 patients had surgical treatment, 49 patients were treated with an enema, 1 patient had an enema and surgery, and 1 patient resolved spontaneously.
Pancreatic Insufficiency and CFTR Genotype Are Correlated With MI
Approximately 95% of CF patients have pancreatic insufficiency (PI), and prior studies of MI have shown a close correlation between pancreatic status and MI. 1 Indeed, 159 of the 160 MI patients in this study were diagnosed with PI. As expected, pancreatic sufficiency (PS) was present at a higher rate in patients without MI (91 of 762; 12%; P ϭ 3 ϫ 10 Ϫ7 ). Because MI correlates with pancreatic status, and pancreatic status correlates with CFTR genotype, we expected that MI also should correlate with CFTR genotype. As predicted, the common CF mutation ⌬F508, which is highly associated with PI, was found at increased frequency in MI vs non-MI patients (79% vs 68%; P ϭ 9 ϫ 10 Ϫ5 ), and homozygosity for ⌬F508 also was increased in MI vs non-MI patients (64% vs 47%; P ϭ 2 ϫ 10 Ϫ4 ). Furthermore, of the 39 CFTR genotypes found in patients with PS in this study, only 1 genotype (⌬F508/2184insA) also occurred in a patient with MI: the single MI patient who remains PS (complete list of CFTR mutations available from corresponding author). Intriguingly, 31 patients with PI carried one mutation observed in PS patients, and none of these patients had MI, whereas among 784 PI patients with no PS mutations, 153 had MI (P ϭ .002). The latter observation suggests that CFTR genotype is more predictive of MI than pancreatic status. To test this concept, we selected only PI patients and recalculated the frequency of the ⌬F508 mutation and the frequency of homozygosity for ⌬F508 in MI vs non-MI patients. Both ⌬F508 and homozygosity for ⌬F508 were found at greater frequency in MI patients than in non-MI patients (⌬F508 allele frequency: 79% vs 73%, P ϭ .02; ⌬F508 homozygote frequency: 64% vs 54%, P ϭ .01). Finally, we performed a multivariate regression analysis in which PI was subdivided based on the number of ⌬F508 alleles. As shown in Table 1 , PI with ⌬F508 homozygosity was an independent risk factor for MI (odds ratio, 13.0). PI in the context of other CFTR genotypes had a large effect size (odds ratio, 7.8 -8.4) but was of borderline significance. Thus, although PI is highly correlated with MI, CFTR genotype can decrease the association with MI (eg, PS mutations) or increase the association with MI (eg, ⌬F508 homozygosity) in PI patients.
Complications Correlated With MI and Mode of Treatment of MI
To determine if other features of CF were correlated with MI, a series of disease characteristics (listed in the Mate-rials and Methods section) was tested for association with MI by single and multiple logistic regression analysis. In addition to pancreatic status and CFTR genotype (shown earlier), MI also was correlated with DIOS, DIOS treated surgically, increased transaminase levels, age, decreased body mass index Z-score, and B cepacia-positive culture (Table 1) . We then considered treatment modality (surgical vs nonsurgical) for MI under the hypothesis that surgical treatment is a marker for more severe intestinal disease. By multiple regression analysis, the only variable significantly correlated with treatment mode for MI was DIOS (odds ratio of having had surgery ϭ 2.6; 95% confidence interval, 1.1-5.9; P ϭ .03). Further examination of DIOS and MI revealed that the rate of DIOS in patients without MI (96 of 733; 13%) was lower than for patients with MI treated surgically (52 of 155; 34%; P ϭ 9 ϫ 10 Ϫ9 ), but about the same in patients with MI treated nonsurgically (10 of 51; 20%; P ϭ .2). Of note, CFTR genotype was not correlated with MI treatment modality. No significant correlation between MI or MI treatment modality was observed for sex or other markers for CF disease severity.
Modifier Genes Contribute Substantially to MI
To determine if genetic or nongenetic factors cause MI, we compared the rates of concordance for MI among affected twin pairs and sibling sets, who share both copies of CFTR but otherwise have different degrees of gene sharing (Table 2) . Among families in which at least one member had MI, MZ twins show significantly greater concordance than DZ twins and siblings. Concordance rates for MI did not differ between DZ twins and siblings. In the subjects homozygous for ⌬F508, concordance rates were similarly greater among MZ twins (11 of 13 MZ twin pairs; 1 of 5 DZ twin pairs, P ϭ .02; 12 of 44 sibling pairs, P ϭ .0003; 2 of 6 sibling trios, P ϭ .05). It is possible that intestinal obstruction caused by MI may affect all CF patients but common protective factors (genetic and otherwise) prevent the development of this complication in most patients. A protective role for modifying factors of MI is suggested by the observation that intestinal obstruction is a consistent rather than uncommon complication in the murine model of CF. 15 The concordance rates for the absence of MI are significantly greater in MZ twins than in DZ twins or sibling sets (Table 2) . Concordance for lack of MI did not differ between DZ twins and siblings, and results were essentially identical when restricting analysis to homozygous ⌬F508 subjects (not shown). Finally, we investigated whether sharing the mode of MI treatment correlated with the degree of gene sharing. However, MZ twins did not differ from DZ twins or 2 affected siblings when distributed according to treatment modality (both treated with surgery; one treated with surgery and the other treated with enema; both treated with enema; data not shown). These data show that MZ twins show greater concordance in both causative and protective models for MI, suggesting predominance of genetic factors in each model.
Modifier Genes Do Not Contribute Substantially to DIOS
Because DIOS was correlated highly with surgically treated MI, and DIOS and MI have similar clinical manifestations, 8, 36 we explored the possibility that they have the same genetic cause. As compared with MI, the ⌬F508 allele of CFTR is less well correlated with DIOS. Although the frequency of the ⌬F508 allele is greater (76% vs 70%; P ϭ .02) in subjects with DIOS, the frequency of ⌬F508 homozygosity is similar (58% vs 50%; P ϭ .1). Furthermore, DIOS occurred at similar rates (20%) in subjects homozygous for ⌬F508 and in those with other CFTR genotypes (15%; P ϭ .08). In striking contrast to MI, the concordance rates for DIOS (Table 3) are low in MZ twins, and MZ twins and sibling pairs have similar concordance rates (P ϭ .5; Fisher exact test), indicating that genetic factors do not play a major role in DIOS. We estimated that these patients provided 80% power for detecting a rate difference greater than .25. Concordance rates could not be estimated precisely in DZ twins and 3 affected sibling sets owing to small numbers in these groups. Concordance rates for absence of DIOS did not differ among the 2-member groups; the decrease in concordance for lack of DIOS among sets of 3 siblings is no longer present when siblings in each set of 3 are taken pairwise (concordance rate, 75%). DIOS concordance rates for ⌬F508 homozygotes were similarly low in all twin and sibling groups (1 of 11 MZ twin pairs; 0 of 3 DZ twin pairs, P ϭ 1; 7 of 34 sibling pairs, P ϭ .7; 0 of 4 sibling trios, P ϭ 1). No significant differences were seen in the concordance for lack of DIOS in ⌬F508 homozygote twin and sibling groups (not shown). The frequency of DIOS is not significantly different among MZ twins and siblings, whereas DZ twins have a trend toward a lower rate that likely reflects their younger median age. To assess whether the study population adequately captured the range of ages at which DIOS usually is diagnosed, we compared the mean age at diagnosis of DIOS with the mean age of the entire twin or sibling groups. For the MZ twins and the siblings, the mean age at diagnosis of DIOS was lower (12.0 and 9.0 y, respectively) than the mean age of the MZ twins and siblings (15.5 and 13.4 y, respectively). Only 5 of 47 DZ twins/triplets were diagnosed with DIOS (average age at diagnosis, 6.4 y), likely reflecting the younger mean age of this population (8.4 y), as previously noted. Unlike MI, these results indicate that modifier genes do not contribute substantially to DIOS, suggesting that DIOS and MI have different causes.
Identification of Regions That May Contain MI Modifier Genes
The high rate of concordance for MI among MZ twins compared with DZ twins and siblings (all of whom share CFTR alleles) indicates that one or more modifier genes exist that cause or protect from MI. To identify regions that may contain MI modifier genes, we performed a genome-wide linkage analysis using STR polymorphisms. Because CFTR genotype contributes to MI risk, linkage analysis also was performed on the subset of subjects who were homozygous for the ⌬F508 mutation. Forty-six patients with MI who had at least one sibling with MI (2 DZ twin pairs, 18 sibling pairs, and 2 sibling trios; total, 26 pairs) and all available parents were genotyped for 402 STR markers with an average spacing of 10 cM. Of these patients, 34 were homozygous for ⌬F508 (14 pairs and 2 trios; total, 20 pairs). Identity-by-descent allele-sharing methods were used to identify regions linked to MI. The only region showing significant linkage (logarithm of odds of linkage [LOD] Ͼ3.0) encompassed the CFTR gene on chromosome 7 (multipoint nonparametric LOD score, 4.17; see Figure 1A , OE). Peaks suggestive of linkage (LOD Ͼ2.0) were detected on chromosomes 8p23.1 (LOD 2.14) and 11q25 (LOD 2.18) ( Figure 1B and C, OE) . When analysis was restricted to ⌬F508 homozygotes concordant for MI, the odds of linkage diminished for all 3 peaks (Table 4) . To search for genes that protect CF patients from developing MI, we performed a linkage analysis using 282 pairs (224 nuclear families, 16 trios, and 1 set of 5) concordant for the absence of MI. No regions of linkage with an LOD score greater than 2.0 were found when all CFTR genotypes were included (not shown). Because this group without MI includes individuals who may not be susceptible to MI (such as patients with PS), a second analysis was restricted to 128 pairs of ⌬F508 homozygotes, all with PI (97 nuclear families, 7 trios, and 1 set of 5). Suggestive LOD scores were found on chromosomes 20p11.22 (2.20) and 21q22.3 (2.38); the LOD score for the STR marker nearest to CFTR was 11.35 ( Figure 2) . Thus, multiple loci of suggestive linkage for causative or protective MI modifier genes were found.
To evaluate the regions of possible linkage identified with STR markers and to search for additional regions of linkage, we performed a high-density linkage analysis on the same group of families concordant for the presence of MI (26 affected sibling pairs) using the Affymetrix Centurion SNP array. A total of 90,689 SNPs with an average spacing of 34 Kb were genotyped. As expected for a denser marker map, the peak LOD score for the region encompassing the CFTR gene was increased (multipoint nonparametric LOD 6.96), and the region of maximal linkage was narrower (0.6 cM) than in the STR analysis ( Figure  1A , solid line). Linkage peaks again were found on chromosomes 8 and 11, although the LOD scores were lower ( Figure 1B and C, solid lines; Table 4 ). The only region with LOD near 2.0 in the SNP analysis was on chromosome 4q35.1 (nonparametric LOD, 1.96; Figure 1D , solid line), a region whose nearest marker in the previous 10-cM STR map had an LOD score of 1.62. In analysis restricted to the 20 pairs of MI-concordant ⌬F508 homozygotes, LOD scores for CFTR on chromosome 7 and for loci on chromosomes 8 and 11 decreased (Table 4) , whereas the peak LOD on chromosome 4 increased to 2.42 ( Figure 1D , dashed line). Thus, the SNP map improved the sensitivity and resolution for detecting CFTR linkage on chromosome 7 and provided evidence of linkage to MI, in ⌬F508 homozygotes, on chromosome 4q35.1.
MI Is Not Linked To the CFM-1 Locus on Chromosome 19q13
MI was linked previously to the CFM1 region on chromosome 19q13, but our genome-wide analyses with low-and highdensity marker maps did not reveal a linkage peak on this chromosome ( Figure 3A ). To provide a direct comparison with previously used STR markers, we typed 7 STR markers spanning 6.5 Mb of the CFM1 region in a subset of the earlier-described group, including 24 pairs concordant for the presence of MI, 65 discordant pairs, and 130 pairs without MI. Analyses were performed on the entire group and on those concordant for MI or lack of MI. Five of the 7 markers were the same as those used in the study by Zielenski et al 17 (D19S219, D19S112, D9S412, D19S902, and D19S604; Figure 3 , solid diamonds). The highest nonparametric LOD score was 0.14 for all pairs (0.42 in MI concordant pairs). Under recessive, dominant, and additive models of inheritance, LOD scores never exceeded 0.00 (0.06 in the concordant pairs) and the heterogeneous LOD scores never exceeded 0.25 (0.08 in the concordant pairs). Analysis to evaluate linkage to a protective allele on chromosome 19q13 produced a LOD score of 0.42 (0.67 in pairs concordant for the absence of MI and 1.18 when restricted to ⌬F508 homozygotes). As a second means of assessing linkage, haplotypes were constructed manually based on identityby-state from markers D19S217, D19S219, and D19S112 for the siblings concordant for MI, discordant for MI, or unaffected with MI. The proportion of siblings sharing 0, 1, or 2 haplotypes across the region did not deviate from the expected distribution of 25%, 50%, and 25%, respectively (P ϭ 1, 2 ) . Finally, to evaluate for a Siblings were corrected for age difference by determining the DIOS status of each sibling at the age of the youngest sibling in the sibship. b Includes 9 sets of 3 siblings in which 1 member had DIOS and 3 sets in which 2 members had DIOS.
genetic heterogeneity, 5 sets of concordant siblings that did not share at least one haplotype and 14 sets of discordant siblings sharing both haplotypes were excluded, and the linkage analysis was repeated. Without these families, the highest LOD score was 0.40 (1.74 in the concordant pairs). Thus, we found no evidence for linkage of MI to the CFM1 locus in this sample of CF twins and siblings.
Discussion
CF, similar to many other so-called single-gene disorders, displays considerable variability that cannot be attributed to allelic differences in the disease-causing gene. 3 MI is a wellrecognized complication of CF that has been a paradigm for the elucidation of modifying factors. 37 Prior studies of CF siblings documented that familial recurrence of MI exceeded the incidence of MI in unrelated patients. 4, [11] [12] [13] 17 However, siblings share not only 50% of their genes, but they also have similar environmental exposures (eg, parents, home, clinic). The significantly higher concordance rate of MI in affected MZ twins who share 100% of their genes, compared with affected DZ twins who share 50% of their genes, indicates that genetic factors are likely to play a substantial role in MI. Although acknowledging that the number of study subjects was small, we can estimate that the contribution of genetic variation (heritability) to developing MI approaches 1.0 (heritability ϭ 2 (MZ concordance Ϫ DZ concordance) 28 ). A more robust estimate that considers the disease prevalence 27 is required to estimate heritability for the absence of MI (which occurs in ϳ85% of the CF population). Heritability estimates for lack of MI also approach 1.0 (0.80 -1.4 as estimated by DZ and sibling pairs, respectively). Thus, there is evidence for the presence of both protective and susceptibility modifier genes for MI.
Comparison of the recurrence rates of MI among twins and siblings facilitates predictions of the penetrance, number, and inheritance pattern of the modifier gene(s). The high rate of concordance in the MZ twins suggests that penetrance of genetic factors is high (eg, Ͼ80%). In the 2 affected sibling sets, 19 pairs were concordant for MI and 61 pairs were discordant, indicating a sibling recurrence rate of 0.24. Within the 10 sets of 3 affected siblings with MI (2 concordant sets and 8 discordant sets, see Table 3 Although the classic twin study has proven to be a reliable means of distinguishing the effects of shared environment from shared genes, potential limitations have been discussed. 38 For example, although it is commonly agreed that MZ and DZ twins have similar degrees of shared environment, there have been examples in which MZ twins have a unique shared environment (eg, placenta), causing increased concordance rates in MZ twins leading to an inflated estimate of heritability. 38 At this point, we cannot exclude this possibility. Furthermore, the collection of DZ twins in this study had an excess of males, indicating an incomplete ascertainment of this group, so the concordance rates in DZ twins may be different than calculated. This could alter our heritability estimates, possibly increasing the predicted role for nongenetic factors. The presence of 3 sets of MZ twins discordant for MI in this study and the published report of an MZ pair discordant for MI 39 indicate that nonheritable factor(s) play a role in MI. Nevertheless, the present findings, particularly the high rate of concordance in MZ twins, support the conclusion that the risk for MI primarily is inherited.
Although MI has been reported in a few patients who do not manifest CF, 40, 41 MI in CF patients almost always has been reported in the context of PI. 1 Exocrine pancreatic function in CF patients depends on the underlying mutations in CFTR, with mutations resulting in loss of CFTR function almost invariably associated with PI. Although most of the patients with MI in this study had PI, we discovered that the frequency of MI in PI patients differed depending on CFTR genotype. These results suggest that the CFTR genotype affects the risk for MI beyond its role in determining pancreatic status. This conclusion is consistent with prior studies of unrelated CF patients. CF patients bearing the G551D mutation have been shown to have a lower rate of MI than those homozygous for ⌬F508, even though both mutations almost invariably are associated with PI. 42, 43 Thus, MI appears to be the consequence of interaction between the CFTR gene and MI modifier genes.
Cross-sectional and longitudinal studies indicate that CF patients with MI follow a different course than those without MI. 6, 44, 45 Some have suggested that complications arising from surgical treatment of MI are the primary reason for this difference. 46 To determine if the effect of MI modifier genes extends to other manifestations of CF, we performed multivariate regression analysis to identify significant covariates of MI. In addition to pancreatic status and CFTR genotype, we found that MI was correlated highly with several other gastrointestinal manifestations of CF including increased liver enzyme levels, DIOS, and reduced body mass index. An inverse correlation with increasing age suggests that the strict criteria for diagnosis of MI in the current study are more difficult to fulfill in older patients (eg, for whom neonatal records are less accessible); alternatively, this could reflect a shorter life expectancy for MI patients, as has been reported. 6 Although MI was associated with B cepacia infection, we were unable to correlate MI with any other markers of pulmonary disease severity. MI has been associated previously with liver disease, 47 poorer nutritional outcomes, 48 and DIOS, 46 although correlation with mode of MI treatment was not addressed specifically in these studies. The clinical and pathologic similarities between DIOS and MI have suggested a common cause. 8, 9, 46 However, our concordance analysis suggests that MI and DIOS are caused by different modifying factors. At present, the complexity of covariate analysis is limited by the number of patients in the study; more exhaustive evaluation of possible covariates of MI and of DIOS will be performed when recruitment for the CF Twin and Sibling Study has been completed.
Genome-wide linkage analyses did not identify a single major locus for MI, although we had ample power as indicated by the significant LOD scores obtained for the region encompassing CFTR. Instead, multiple loci with LOD scores suggestive of linkage were identified, in agreement with expectations from sibling recurrence risks (described earlier). Although it is clear that the data support a polygenic origin for MI, further studies are required to determine whether the identified loci contain modifier genes for MI. Of note, the peak on chromosome 11q25 is in a region of conserved synteny with a segment of mouse chromosome 9 associated with intestinal obstruction in a CF mouse model. 49 Two additional points are worth noting. First, the high density map composed of SNP markers localized CFTR on chromosome 7 with a substantially higher LOD score and better defined peak of linkage than the coarse map composed of STR markers. This pattern is expected for a linkage region containing a bona fide trait-causing gene. Although the highdensity map showed lower odds of linkage than the STR map for chromosomes 8p23.1 and 11q25, it did increase for a region on chromosome 4 that had an LOD score in the coarse STR map that did not exceed the threshold of suggestive linkage (LOD Ն 2.0). 50 The LOD score for chromosome 4q35.1 was enhanced further when linkage analysis was restricted to ⌬F508 homozygotes despite a reduction in the number of pairs analyzed from 26 to 20. The latter behavior is consistent with evidence that CFTR genotype influences risk of developing MI. Under this circumstance, one would predict that restricting linkage analysis to patients bearing high-risk CFTR genotypes should optimize the power to detect MI modifier genes. Second, we were unable to detect the previously reported linkage of MI NOTE. Analyses are shown from all CFTR genotypes (All) and ⌬F508 homozygotes (⌬F508/⌬F508); n refers to the number of pairs.
to a locus on chromosome 19q13. 17 The power to detect linkage to a single locus in the previous study at an ␣ value of 0.05 was 68%, 35%, and 58% under a recessive, additive, or dominant model, respectively. The power of this study to detect linkage at the same ␣ value was 92% under a recessive model, 56% under an additive model, and 80% under a dominant model. Furthermore, removal of unambiguously unlinked sibling pairs from the analysis did not expose linkage disguised by locus heterogeneity. There are several possible reasons for the difference between our result and that of Zielenski et al. 17 MI may be the consequence of multiple modifier genes as suggested by studies of the CF mouse, 16, 49 and the results of the linkage scans presented here. Differences in the stratification of the sibling populations including differences in CFTR genotype prevalence may have exposed a modifier gene of minor effect on chromosome 19 in the initial study but not in the current study. Finally, the diagnosis of MI involves subjective criteria that may have led to differences in the phenotyping of the MI populations in each study. In summary, we have used the classic twin design to estimate the contribution of genetic and nongenetic modifiers to a well-known recognized complication of CF. Demonstration that genetic modifiers contribute substantially to MI justifies efforts to identify MI modifier genes by virtue of their location. Evidence that CFTR genotype contributes to MI risk emphasizes the importance of considering this variable in future modifier studies of MI. Our results indicating that MI is polygenic will aid in the design of future searches for modifier genes responsible for this intestinal complication. 
